-
公开(公告)号：SK284040B6
公开(公告)日：2004-08-03
申请号：SK106298
申请日：1997-02-10
Applicant: ABBOTT LAB BERMUDA LTD
Inventor： SALFELD JOCHEN G , ALLEN DEBORAH J , KAYMAKCALAN ZEHRA , LABKOVSKY BORIS , MANKOVICH JOHN A , MCGUINNESS BRIAN T , ROBERTS ANDREW J , SAKORAFAS PAUL , HOOGENBOOM HENDRICUS R J M , SCHOENHAUT DAVID , VAUGHAN TRISTAN J , WHITE MICHAEL , WILTON ALISON J
IPC: C12N15/09 , A61K31/00 , A61K31/40 , A61K31/403 , A61K31/404 , A61K31/415 , A61K31/4164 , A61K31/4178 , A61K31/505 , A61K31/517 , A61K31/52 , A61K31/529 , A61K31/57 , A61K31/573 , A61K31/675 , A61K38/00 , A61K38/04 , A61K38/16 , A61K39/39 , A61K39/395 , A61P1/00 , A61P1/04 , A61P1/16 , A61P3/10 , A61P7/00 , A61P7/04 , A61P9/00 , A61P9/04 , A61P9/10 , A61P11/00 , A61P11/16 , A61P13/12 , A61P17/00 , A61P17/02 , A61P19/02 , A61P19/06 , A61P25/00 , A61P27/02 , A61P29/02 , A61P31/00 , A61P31/04 , A61P31/12 , A61P31/18 , A61P33/06 , A61P35/00 , A61P35/04 , A61P37/00 , A61P37/02 , A61P37/06 , A61P37/08 , A61P39/02 , C07K16/24 , C12N1/21 , C12N5/10 , C12P21/08 , G01N33/53 , G01N33/543 , G01N33/564 , G01N33/576 , G01N33/68 , C12N15/13 , C12N15/64
Abstract: Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor 'alpha' (hTNF'alpha') are disclosed. These antibodies have high affinity for hTNF'alpha'(e.g., Kd = 10exp(-8) M or less), a slow off rate for hTNF'alpha' dissociation (e.g., Koff = 10exp(-3) sec-1 or less) and neutralize hTNF'alpha' activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hTNF'alpha' and for inhibiting hTNF'alpha' activity, e.g., in a human subject suffering from a disorder in which hTNF'alpha' activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.
-
公开(公告)号：NO20023788D0
公开(公告)日：2002-08-09
申请号：NO20023788
申请日：2002-08-09
Applicant: ABBOTT LAB
Inventor： GHAYUR TARIQ , DIXON RICHARD WOODWARD , ROGUSKA MICHAEL , WHITE MICHAEL , LABKOVSKY BORIS , SALFELD JOCHEN G , DUNCAN ALEXANDER R , BROCKLEHURST SIMON MARK , MANKOVICH JOHN A , SHORROCK CELIA PATRICIA , THOMPSON JULIA ELIZABETH , LENNARD SIMON NICHOLAS
IPC: A61K39/395 , A61K45/00 , C12N15/02 , A61P1/04 , A61P3/10 , A61P5/14 , A61P7/00 , A61P7/02 , A61P7/06 , A61P9/04 , A61P9/10 , A61P9/12 , A61P11/00 , A61P11/06 , A61P13/12 , A61P15/00 , A61P17/00 , A61P17/06 , A61P17/14 , A61P19/02 , A61P25/14 , A61P25/16 , A61P25/18 , A61P25/24 , A61P25/28 , A61P29/00 , A61P31/00 , A61P31/04 , A61P31/12 , A61P33/00 , A61P35/00 , A61P37/00 , A61P37/02 , A61P37/06 , A61P37/08 , A61P39/00 , A61P39/02 , C07K16/24 , C12N1/15 , C12N1/19 , C12N1/21 , C12N5/10 , C12P21/08 , C07K
Abstract: Antibodies that bind human interleukin-18 (hIL-18) are provided, in particular, antibodies that bind epitope(s) of human IL-18. The antibodies can be, for example, entirely human antibodies, recombinant antibodies, or monoclonal antibodies. Preferred antibodies have high affinity for hIL-18 and neutralize hIL-18 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-18 and for inhibiting hIL-I8 activity, e.g., in a human subject suffering from a disorder in which hIL-18 activity is detrimental.
-
公开(公告)号：AU775499B2
公开(公告)日：2004-08-05
申请号：AU6664900
申请日：2000-10-20
Applicant: ABBOTT LAB BERMUDA LTD
-
公开(公告)号：AU2004202769A1
公开(公告)日：2004-07-15
申请号：AU2004202769
申请日：2004-06-23
Applicant: ABBOTT LAB BERMUDA LTD
-
公开(公告)号：PT929578E
公开(公告)日：2003-09-30
申请号：PT97906572
申请日：1997-02-10
Applicant: ABBOTT LAB BERMUDA LTD
Inventor： WHITE MICHAEL , WILTON ALISON JANE , SALFELD JOCHEN G , ALLEN DEBORAH J , KAYMAKCALAN ZEHRA , LABKOVSKY BORIS , MANKOVICH JOHN A , MCGUINESS BRIAN T , ROBERTS ANDREW J , SAKORAFAS PAUL , HOOGENBOOM HENDRICUS R J M , SCHOENHAUT DAVID , VAUGHAN TRISTAN J
IPC: C12N15/09 , A61K31/00 , A61K31/40 , A61K31/403 , A61K31/404 , A61K31/415 , A61K31/4164 , A61K31/4178 , A61K31/505 , A61K31/517 , A61K31/52 , A61K31/529 , A61K31/57 , A61K31/573 , A61K31/675 , A61K38/00 , A61K38/04 , A61K38/16 , A61K39/39 , A61K39/395 , A61P1/00 , A61P1/04 , A61P1/16 , A61P3/10 , A61P7/00 , A61P7/04 , A61P9/00 , A61P9/04 , A61P9/10 , A61P11/00 , A61P11/16 , A61P13/12 , A61P17/00 , A61P17/02 , A61P19/02 , A61P19/06 , A61P25/00 , A61P27/02 , A61P29/02 , A61P31/00 , A61P31/04 , A61P31/12 , A61P31/18 , A61P33/06 , A61P35/00 , A61P35/04 , A61P37/00 , A61P37/02 , A61P37/06 , A61P37/08 , A61P39/02 , C07K16/24 , C12N1/21 , C12N5/10 , C12P21/08 , G01N33/53 , G01N33/543 , G01N33/564 , G01N33/576 , G01N33/68 , C12N15/13 , C12N15/64
Abstract: Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor α (hTNFα) are disclosed. These antibodies have high affinity for hTNFα (e.g., Kd=10−8 M or less), a slow off rate for hTNFα dissociation (e.g., Koff=10−3 sec−1 or less) and neutralize hTNFα activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hTNFα and for inhibiting hTNFα activity, e.g., in a human subject suffering from a disorder in which hTNFα activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.
-
Patent Agency Ranking
公开(公告)号：RO123028B1
公开(公告)日：2010-07-30
申请号：RO200500050
申请日：1997-02-10
Applicant: ABBOTT LAB BERMUDA LTD
Inventor： SALFELD JOCHEN G , ALLEN DEBORAH J , KAYMAKCALAN ZEHRA , LABKOVSKY BORIS , MANKOVICH JOHN A , MCGUINNESS BRIAN T , ROBERTS ANDREW J , SAKORAFAS PAUL , HOOGENBOOM HENDRICUS R J M , SCHOENHAUT DAVID , VAUGHAN TRISTAN J , WHITE MICHAEL , WILTON ALISON J
IPC: C07K14/525 , C12N15/09 , A61K31/00 , A61K31/40 , A61K31/403 , A61K31/404 , A61K31/415 , A61K31/4164 , A61K31/4178 , A61K31/505 , A61K31/517 , A61K31/52 , A61K31/529 , A61K31/57 , A61K31/573 , A61K31/675 , A61K38/00 , A61K38/04 , A61K38/16 , A61K39/39 , A61K39/395 , A61P1/00 , A61P1/04 , A61P1/16 , A61P3/10 , A61P7/00 , A61P7/04 , A61P9/00 , A61P9/04 , A61P9/10 , A61P11/00 , A61P11/16 , A61P13/12 , A61P17/00 , A61P17/02 , A61P19/02 , A61P19/06 , A61P25/00 , A61P27/02 , A61P29/02 , A61P31/00 , A61P31/04 , A61P31/12 , A61P31/18 , A61P33/06 , A61P35/00 , A61P35/04 , A61P37/00 , A61P37/02 , A61P37/06 , A61P37/08 , A61P39/02 , C07K16/24 , C12N1/21 , C12N5/10 , C12P21/08 , G01N33/53 , G01N33/543 , G01N33/564 , G01N33/576 , G01N33/68
Abstract: Invenţia se referă la un anticorp recombinant uman, care se leagă la factorul de necroză umană alpha (hTNF alpha ) care are afinitate pentru hTNFalpha, Kd = 10-8M sau mai mică, şi o constantă a vitezei Koff de 1 x 10-3s-1 sau mai mică, şi neutralizează activitatea in vitro şi in vivo, precum şi la un acid nucleic care îl codifică, celula gazdă care cuprinde un vector de expresie recombinant, precum şi la o compoziţie farmaceutică ce cuprinde anticorpul, administrată în tratamentul bolilor în care activitatea TNFalfa este dăunătoare.
-
公开(公告)号：CZ292465B6
公开(公告)日：2003-09-17
申请号：CZ247698
申请日：1997-02-10
Applicant: ABBOTT LAB BERMUDA LTD
Inventor： SALFELD JOCHEN G , ALLEN DEBORAH J , KAYMAKCALAN ZEHRA , LABKOVSKY BORIS , MANKOVICH JOHN A , MCGUINNESS BRIAN T , ROBERTS ANDREW J , SAKORAFAS PAUL , HOOGENBOOM HENDRICUS R J M , SCHOENHAUT DAVID , VAUGHAN TRISTAN J , WHITE MICHAEL , WILTON ALISON J
IPC: C12N15/09 , A61K31/00 , A61K31/40 , A61K31/403 , A61K31/404 , A61K31/415 , A61K31/4164 , A61K31/4178 , A61K31/505 , A61K31/517 , A61K31/52 , A61K31/529 , A61K31/57 , A61K31/573 , A61K31/675 , A61K38/00 , A61K38/04 , A61K38/16 , A61K39/39 , A61K39/395 , A61P1/00 , A61P1/04 , A61P1/16 , A61P3/10 , A61P7/00 , A61P7/04 , A61P9/00 , A61P9/04 , A61P9/10 , A61P11/00 , A61P11/16 , A61P13/12 , A61P17/00 , A61P17/02 , A61P19/02 , A61P19/06 , A61P25/00 , A61P27/02 , A61P29/02 , A61P31/00 , A61P31/04 , A61P31/12 , A61P31/18 , A61P33/06 , A61P35/00 , A61P35/04 , A61P37/00 , A61P37/02 , A61P37/06 , A61P37/08 , A61P39/02 , C07K16/24 , C12N1/21 , C12N5/10 , C12P21/08 , G01N33/53 , G01N33/543 , G01N33/564 , G01N33/576 , G01N33/68 , C12N15/13 , C12N15/64
Abstract: Human antibodies, preferably recombinant human antibodies that specifically bind to human tumor necrosis factor alpha (hTNF alpha) are described. These antibodies have high affinity for hTNF alpha (e.g., Kid = =10e-3se-1 or less), a slow off rate for hTNF alpha dissociation (e.g., Koff = 10 sec or less) and neutralize hTNF alpha activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hTNF alpha and for inhibiting hTNF alpha activity, e.g., in a human subject suffering from a disorder in which hTNF alpha activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.
-
公开(公告)号：DK0929578T3
公开(公告)日：2003-08-25
申请号：DK97906572
申请日：1997-02-10
Applicant: ABBOTT LAB BERMUDA LTD
Inventor： SALFELD JOCHEN G , ALLEN DEBORAH J , KAYMAKCALAN ZEHRA , LABKOVSKY BORIS , MANKOVICH JOHN A , MCGUINESS BRIAN T , ROBERTS ANDREW J , SAKORAFAS PAUL , HOOGENBOOM HENDRICUS R J M , SCHOENHAUT DAVID , VAUGHAN TRISTAN J , WHITE MICHAEL , WILTON ALISON J
IPC: C12N15/09 , A61K31/00 , A61K31/40 , A61K31/403 , A61K31/404 , A61K31/415 , A61K31/4164 , A61K31/4178 , A61K31/505 , A61K31/517 , A61K31/52 , A61K31/529 , A61K31/57 , A61K31/573 , A61K31/675 , A61K38/00 , A61K38/04 , A61K38/16 , A61K39/39 , A61K39/395 , A61P1/00 , A61P1/04 , A61P1/16 , A61P3/10 , A61P7/00 , A61P7/04 , A61P9/00 , A61P9/04 , A61P9/10 , A61P11/00 , A61P11/16 , A61P13/12 , A61P17/00 , A61P17/02 , A61P19/02 , A61P19/06 , A61P25/00 , A61P27/02 , A61P29/02 , A61P31/00 , A61P31/04 , A61P31/12 , A61P31/18 , A61P33/06 , A61P35/00 , A61P35/04 , A61P37/00 , A61P37/02 , A61P37/06 , A61P37/08 , A61P39/02 , C07K16/24 , C12N1/21 , C12N5/10 , C12P21/08 , G01N33/53 , G01N33/543 , G01N33/564 , G01N33/576 , G01N33/68 , C12N15/13 , C12N15/64
Abstract: Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor α (hTNFα) are disclosed. These antibodies have high affinity for hTNFα (e.g., Kd=10−8 M or less), a slow off rate for hTNFα dissociation (e.g., Koff=10−3 sec−1 or less) and neutralize hTNFα activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hTNFα and for inhibiting hTNFα activity, e.g., in a human subject suffering from a disorder in which hTNFα activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.
-
公开(公告)号：PL188192B1
公开(公告)日：2004-12-31
申请号：PL32841197
申请日：1997-02-10
Applicant: ABBOTT LAB BERMUDA LTD
Inventor： SALFELD JOCHEN G , ALLEN DEBORAH J , KAYMAKCALAN ZEHRA , LABKOVSKY BORIS , MANKOVICH JOHN A , MCGUINESS BRIAN T , ROBERTS ANDREW J , SAKORAFAS PAUL , HOOGENBOOM HENDRICUS R J M , SCHOENHAUT DAVID , VAUGHAN TRISTAN J , WHITE MICHAEL , WILTON ALISON J
IPC: C12N15/09 , A61K31/00 , A61K31/40 , A61K31/403 , A61K31/404 , A61K31/415 , A61K31/4164 , A61K31/4178 , A61K31/505 , A61K31/517 , A61K31/52 , A61K31/529 , A61K31/57 , A61K31/573 , A61K31/675 , A61K38/00 , A61K38/04 , A61K38/16 , A61K39/39 , A61K39/395 , A61P1/00 , A61P1/04 , A61P1/16 , A61P3/10 , A61P7/00 , A61P7/04 , A61P9/00 , A61P9/04 , A61P9/10 , A61P11/00 , A61P11/16 , A61P13/12 , A61P17/00 , A61P17/02 , A61P19/02 , A61P19/06 , A61P25/00 , A61P27/02 , A61P29/02 , A61P31/00 , A61P31/04 , A61P31/12 , A61P31/18 , A61P33/06 , A61P35/00 , A61P35/04 , A61P37/00 , A61P37/02 , A61P37/06 , A61P37/08 , A61P39/02 , C07K16/24 , C12N1/21 , C12N5/10 , C12P21/08 , G01N33/53 , G01N33/543 , G01N33/564 , G01N33/576 , G01N33/68 , C12N15/13 , C12N15/64
Abstract: Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor α (hTNFα) are disclosed. These antibodies have high affinity for hTNFα (e.g., Kd=10−8 M or less), a slow off rate for hTNFα dissociation (e.g., Koff=10−3 sec−1 or less) and neutralize hTNFα activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hTNFα and for inhibiting hTNFα activity, e.g., in a human subject suffering from a disorder in which hTNFα activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.
-
公开(公告)号：ES2198552T3
公开(公告)日：2004-02-01
申请号：ES97906572
申请日：1997-02-10
Applicant: ABBOTT LAB BERMUDA LTD
Inventor： SALFELD JOCHEN G , ALLEN DEBORAH J , KAYMAKCALAN ZEHRA , LABKOVSKY BORIS , MANKOVICH JOHN A , MCGUINESS BRIAN T
IPC: C12N15/09 , A61K31/00 , A61K31/40 , A61K31/403 , A61K31/404 , A61K31/415 , A61K31/4164 , A61K31/4178 , A61K31/505 , A61K31/517 , A61K31/52 , A61K31/529 , A61K31/57 , A61K31/573 , A61K31/675 , A61K38/00 , A61K38/04 , A61K38/16 , A61K39/39 , A61K39/395 , A61P1/00 , A61P1/04 , A61P1/16 , A61P3/10 , A61P7/00 , A61P7/04 , A61P9/00 , A61P9/04 , A61P9/10 , A61P11/00 , A61P11/16 , A61P13/12 , A61P17/00 , A61P17/02 , A61P19/02 , A61P19/06 , A61P25/00 , A61P27/02 , A61P29/02 , A61P31/00 , A61P31/04 , A61P31/12 , A61P31/18 , A61P33/06 , A61P35/00 , A61P35/04 , A61P37/00 , A61P37/02 , A61P37/06 , A61P37/08 , A61P39/02 , C07K16/24 , C12N1/21 , C12N5/10 , C12P21/08 , G01N33/53 , G01N33/543 , G01N33/564 , G01N33/576 , G01N33/68 , C12N15/13 , C12N15/64
Abstract: Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor α (hTNFα) are disclosed. These antibodies have high affinity for hTNFα (e.g., Kd=10−8 M or less), a slow off rate for hTNFα dissociation (e.g., Koff=10−3 sec−1 or less) and neutralize hTNFα activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hTNFα and for inhibiting hTNFα activity, e.g., in a human subject suffering from a disorder in which hTNFα activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.
-
-
-
-
-
-
-
-
-
Search Results
10
records
(took 0.022 seconds)
